Degraders, bispecifics define translational trends at AACR 

Bispecific antibodies and targeted protein degraders are front and center at this year’s AACR Annual Meeting, driving modality innovation, while post-translational sugar modifications are emerging as a focal point for new target discovery.

In an analysis of abstracts released ahead of the American Association for Cancer Research (AACR) 2025 annual meeting, BioCentury focused on first-in-human clinical trials and new molecular targets — two leading indicators of translation trends. ...